Entresto Shines Brightly Among New Launches In India
Novartis’ Entresto has had a strong run in India, with two second brands in tow, while itraconazole and azilsartan therapies are among the other recent introductions that have gained traction in a competitive market.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Sacubitril/valsartan combination sales surge in India driving growth in the cardiac care segment even as Novartis and challenger Natco slug it out in court over alleged patent infringement charges.
India has seen an uptick in in-licensing deals, with robust growth in the number of novel drugs in such arrangements delivering gains for both the domestic partner and innovator company.